新型肾上腺素β受体阻滞药奈必洛尔在心血管疾病中的应用进展  

Effects of novel beta-adrenergic blocker nebivolol on cardiovascular diseases

作　　者：谢启海 沈伟利[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院上海市高血压研究所上海市血管生物学重点实验室,上海200025

出　　处：《中国新药与临床杂志》2014年第1期1-5,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：国家自然科学基金资助(30871002;81070325)

摘　　要：奈必洛尔是一种新型的第三代肾上腺素β受体阻滞药,对β_1受体具有高选择性,可通过内皮L-精氨酸/一氧化氮途径扩张血管,清除自由基,改善内皮功能,还具有不干扰糖脂代谢、抗血小板聚集等优点。本文综述了奈必洛尔的结构特点、药动学、作用机制和临床研究进展。Nebivolol is a new type of third-generation 13-adrenergic blocker with high setecUvlty for β1- adrenergic receptors, which also causes vasodilation by interaction with the endothelial L- arginine/nitric oxide pathway, scavenges reactive oxygen species and improves endothelial function. No significant changes on glucose and lipid metabolism were noted with nebivolol. Furthermore, nebivolol possess the greatest inhibition effect on platelet aggregation. This paper reviews the pharmacology structure, the pharmacokinetics, mechanism of action and the progress of clinical research of nebivolol.

关 键 词：奈必洛尔 肾上腺素能Β受体拮抗剂 心力衰竭 充血性 高血压 冠心病 

分 类 号：R54[医药卫生—心血管疾病]